Published on 07/06/2026

How Indian Pharma Companies Should Build Pharmacovigilance Compliance Under Revised Schedule M

The CDSCO circular on implementation of pharmacovigilance systems under Schedule M is a major regulatory signal for Indian pharmaceutical companies. It confirms that pharmacovigilance is no longer only a post-marketing documentation activity handled in isolation by regulatory or medical teams. It is now directly connected with GMP compliance, licensing expectations, and inspection readiness.

The circular refers to Para 6.11 of Schedule M, which requires the licensee to have a pharmacovigilance system in place for collecting, processing, and forwarding reports to licensing authorities for information on adverse drug reactions emerging from the use of drugs manufactured or marketed by the licensee.

This wording may appear simple, but its operational impact is significant. It means every manufacturer and marketer covered under the requirement must be able to demonstrate that an effective PV system exists, operates, is documented, and can be verified during inspection.

For many Indian pharma companies, especially small and mid-sized manufacturers, this may be a major compliance gap. Many companies have strong manufacturing documentation, batch records, stability programs, and quality systems, but their pharmacovigilance systems may be informal, incomplete, outsourced without proper oversight, or limited to occasional ADR forwarding.

The new expectation is different. Companies now need a structured and inspection-ready pharmacovigilance framework.

Understanding Para 6.11 of Schedule M

Para 6.11 creates the foundation for pharmacovigilance compliance under Revised Schedule M. The requirement focuses on three core actions: collecting, processing, and forwarding adverse drug reaction reports.

Collection means the company must have mechanisms to receive safety information from relevant sources. These may include healthcare professionals, patients, distributors, medical representatives, product complaint channels, customer care teams, field staff, literature, hospitals, and business partners.

Processing means the company must evaluate received safety information in a structured way. This includes identifying whether the information qualifies as a valid adverse drug reaction report, assessing seriousness, recording product details, documenting patient information where available, performing follow-up where needed, and maintaining traceable records.

Forwarding means the company must submit or communicate relevant safety information to the appropriate licensing authorities within the expected framework. This requires defined responsibility, timelines, documentation, and proof of submission.

The practical message is clear: a company cannot simply say that it will report ADRs when they occur. It must show a working system capable of detecting, handling, reviewing, and reporting safety information.

Why the CDSCO Circular Is Important

The circular is important because it converts the Schedule M pharmacovigilance requirement into an inspection-sensitive compliance expectation. It directs stakeholders to ensure establishment and maintenance of an effective pharmacovigilance system.

Even more importantly, it states that officers of CDSCO, State Licensing Authorities, and Union Territory administrations may verify compliance during routine inspections and other regulatory activities.

This means pharmacovigilance may now become part of the inspection conversation. Inspectors may ask whether the company has a PV system, whether ADRs are collected, whether personnel are trained, whether SOPs exist, whether records are maintained, and whether any safety information has been forwarded to authorities.

This is a major shift for Indian GMP inspections. Traditionally, many inspections focused heavily on manufacturing, premises, documentation, validation, quality control, stability, sanitation, personnel, and quality assurance. With this circular, PV compliance becomes another area that inspectors may examine.

Companies that are not prepared may face observations related to absence of PV systems, inadequate documentation, lack of training, weak ADR escalation, poor complaint-to-PV linkage, or no evidence of compliance monitoring.

What an Effective Pharmacovigilance System Should Include

An effective PV system under Schedule M should be practical, documented, and proportionate to the company’s product portfolio and business model. It does not need to be unnecessarily complex, but it must be real and functional.

At minimum, the system should define how adverse drug reactions are collected, who reviews them, how they are documented, how follow-up is performed, how reportability is assessed, how submissions are made, and how records are retained.

A basic Schedule M-compliant PV system should include:

• Pharmacovigilance policy
• ADR collection and reporting SOP
• Defined PV responsibilities
• Complaint-to-PV escalation process
• Training matrix for relevant personnel
• ADR reporting form or case intake form
• PV register or safety database
• Follow-up documentation process
• Reporting and submission records
• Deviation and CAPA procedure for PV failures
• Management review of PV performance
• Vendor oversight procedure, if PV is outsourced

The key is not to create documents only for inspection. The system must be implemented. Personnel should know what to do if they receive a safety complaint, medical inquiry, product complaint with patient harm, or field information suggesting an adverse reaction.

Integration of PV With GMP and Quality Systems

One of the biggest mistakes companies may make is treating pharmacovigilance as separate from the quality system. Under Revised Schedule M, this approach is risky.

PV should be linked with quality assurance, product complaint handling, deviation management, CAPA, change control, training, vendor qualification, and management review.

For example, a product complaint may initially appear to be a quality issue. But if the complaint includes patient harm, hospitalization, unexpected reaction, lack of efficacy, or medication error, it may also have pharmacovigilance relevance. The complaint handling team must know when to escalate information to PV.

Similarly, repeated ADR patterns may indicate the need for quality investigation, labeling review, training, risk communication, or regulatory notification. This requires cross-functional coordination between QA, regulatory affairs, medical, manufacturing, and PV teams.

CAPA management is also important. If a company fails to report an ADR on time, loses follow-up information, or fails to train field staff, the issue should not be closed informally. It should be investigated, documented, corrected, and prevented from recurring.

Inspection Readiness for Schedule M PV Compliance

Inspection readiness means the company can demonstrate that its PV system exists, operates, and is controlled. This requires more than having an SOP in a folder.

During inspection, officers may ask for evidence such as:

• PV SOPs and policy documents
• ADR reporting forms
• PV training records
• Product complaint escalation records
• PV register or case log
• Submission records to authorities
• Deviation and CAPA records
• Management review minutes
• Vendor agreements, if outsourced
• Evidence of periodic review of PV system effectiveness

Inspectors may also interview personnel. They may ask production, QA, regulatory, warehouse, marketing, complaint handling, or field staff what they would do if they received information about an adverse reaction.

This means training must extend beyond one person in regulatory affairs. Any employee who may receive safety information should understand basic reporting expectations.

Common Gaps Indian Companies Should Fix Immediately

Many companies may discover that they already have some elements of PV compliance but not a complete system. Common gaps may include absence of written SOPs, unclear responsibilities, no ADR form, no complaint-to-PV linkage, no training records, no reporting timeline, no vendor oversight, and no management review.

Another common gap is overdependence on external consultants or service providers without internal ownership. Outsourcing can support PV activities, but the licensee remains responsible for compliance.

Companies should also avoid creating overly complex systems copied from multinational models without considering their own operations. A small manufacturer does not need unnecessary layers, but it does need a practical, traceable, and inspection-ready system.

The best approach is to conduct a gap assessment against Para 6.11, the CDSCO circular, internal product portfolio, complaint system, regulatory obligations, and existing quality procedures.

Step-by-Step Implementation Approach

Companies can begin with a phased implementation model.

Step 1: Conduct a PV gap assessment against Schedule M expectations.

Step 2: Define PV ownership and responsibilities.

Step 3: Create or revise SOPs for ADR collection, processing, reporting, documentation, and escalation.

Step 4: Integrate PV with complaint handling, QA, regulatory affairs, and field operations.

Step 5: Train relevant personnel using role-based training modules.

Step 6: Implement ADR forms, PV registers, tracking logs, and reporting records.

Step 7: Establish deviation and CAPA handling for PV failures.

Step 8: Include PV performance in management review.

Step 9: Conduct internal audit or mock inspection of the PV system.

Step 10: Maintain continuous improvement based on audit findings, regulatory updates, and operational experience.

Future Direction of Pharmacovigilance Under Schedule M

The CDSCO circular is likely only the beginning of a stronger PV compliance environment in India. As inspectors become more familiar with PV requirements, companies should expect more detailed questions during inspections.

Future expectations may include stronger ADR documentation, better integration with quality systems, structured PV metrics, more formal signal review, improved vendor oversight, and periodic PV system review.

Companies that act early will have an advantage. They will be able to demonstrate readiness, maturity, and commitment to patient safety. Companies that delay may face rushed remediation, inspection observations, and reputational risk.

Schedule M pharmacovigilance should therefore be treated as a strategic compliance priority, not a minor documentation update.

Related Articles

• Understanding Para 6.11 of Schedule M
• CDSCO PV Inspection Readiness
• ADR Reporting Workflow Under Schedule M
• PV SOPs for Schedule M Compliance
• PV Audit Findings Under Schedule M

Frequently Asked Questions

Is pharmacovigilance mandatory under Revised Schedule M?

Yes. Para 6.11 requires licensees to maintain a pharmacovigilance system for collecting, processing, and forwarding adverse drug reaction reports to licensing authorities.

Can CDSCO verify PV compliance during GMP inspections?

Yes. The CDSCO circular indicates that CDSCO, State Licensing Authority, and UT administration officers may verify compliance during routine inspections and regulatory activities.

What is the first step for implementation?

The first step is to perform a gap assessment against Schedule M requirements and identify missing SOPs, responsibilities, training, workflows, and records.

Does every company need a separate PV department?

Not necessarily. The system should be proportionate to the company’s size and product portfolio, but responsibilities must be clearly defined and documented.

Can pharmacovigilance be outsourced?

Yes, selected PV activities may be outsourced, but the licensee remains responsible for compliance and must maintain proper vendor oversight.